Global Clinical Oncology Next Generation Sequencing (NGS) Market Insights, Forecast to 2028

Report ID: 1654725 | Published Date: Sep 2024 | No. of Page: 129 | Base Year: 2023 | Rating: 4.3 | Webstory: Check our Web story
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 NGS Pre-Sequencing
        1.2.3 Sequencing
        1.2.4 NGS Data Analysis
        1.2.5 Primary, Secondary & Tertiary Data Analysis
    1.3 Market by Application
        1.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Academic & Clinical Research
        1.3.3 Hospitals & Clinics
        1.3.4 Pharma & Biotech Entities
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2017-2028)
    2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Region
        2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Region (2017-2022)
        2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2023-2028)
    2.3 Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
        2.3.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Trends
        2.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
        2.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
        2.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue
        3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2017-2022)
        3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2017-2022)
    3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
    3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
        3.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2021
    3.5 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
    3.6 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
    3.7 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
    4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2017-2022)
    4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2023-2028)
5 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
    5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Application (2017-2022)
    5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2017-2028)
    6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
        6.2.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022)
        6.2.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028)
        6.2.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2017-2028)
    6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
        6.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022)
        6.3.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028)
        6.3.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2017-2028)
    6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
        6.4.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022)
        6.4.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2017-2028)
    7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
        7.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022)
        7.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028)
        7.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2017-2028)
    7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
        7.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022)
        7.3.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028)
        7.3.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2017-2028)
    7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
        7.4.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022)
        7.4.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (2017-2028)
    8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
        8.2.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2017-2028)
    8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
        8.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2017-2028)
    8.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region
        8.4.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2017-2028)
    9.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
        9.2.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022)
        9.2.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028)
        9.2.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2017-2028)
    9.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
        9.3.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022)
        9.3.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028)
        9.3.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2017-2028)
    9.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
        9.4.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022)
        9.4.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size (2017-2028)
    10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
        10.2.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2017-2028)
    10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
        10.3.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2017-2028)
    10.4 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
        10.4.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Illumina
        11.1.1 Illumina Company Details
        11.1.2 Illumina Business Overview
        11.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.1.5 Illumina Recent Developments
    11.2 Roche
        11.2.1 Roche Company Details
        11.2.2 Roche Business Overview
        11.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.2.5 Roche Recent Developments
    11.3 Agilent Technologies
        11.3.1 Agilent Technologies Company Details
        11.3.2 Agilent Technologies Business Overview
        11.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.3.5 Agilent Technologies Recent Developments
    11.4 Knome
        11.4.1 Knome Company Details
        11.4.2 Knome Business Overview
        11.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.4.5 Knome Recent Developments
    11.5 Genomatix Software
        11.5.1 Genomatix Software Company Details
        11.5.2 Genomatix Software Business Overview
        11.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.5.5 Genomatix Software Recent Developments
    11.6 GATC Biotech
        11.6.1 GATC Biotech Company Details
        11.6.2 GATC Biotech Business Overview
        11.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.6.5 GATC Biotech Recent Developments
    11.7 Oxford Nanopore Technologies
        11.7.1 Oxford Nanopore Technologies Company Details
        11.7.2 Oxford Nanopore Technologies Business Overview
        11.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.7.5 Oxford Nanopore Technologies Recent Developments
    11.8 Macrogen
        11.8.1 Macrogen Company Details
        11.8.2 Macrogen Business Overview
        11.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.8.5 Macrogen Recent Developments
    11.9 Life Technologies
        11.9.1 Life Technologies Company Details
        11.9.2 Life Technologies Business Overview
        11.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.9.5 Life Technologies Recent Developments
    11.10 DNASTAR
        11.10.1 DNASTAR Company Details
        11.10.2 DNASTAR Business Overview
        11.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.10.5 DNASTAR Recent Developments
    11.11 Exosome Diagnostics
        11.11.1 Exosome Diagnostics Company Details
        11.11.2 Exosome Diagnostics Business Overview
        11.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.11.5 Exosome Diagnostics Recent Developments
    11.12 Biomatters
        11.12.1 Biomatters Company Details
        11.12.2 Biomatters Business Overview
        11.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.12.5 Biomatters Recent Developments
    11.13 CLC Bio
        11.13.1 CLC Bio Company Details
        11.13.2 CLC Bio Business Overview
        11.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.13.5 CLC Bio Recent Developments
    11.14 BGI
        11.14.1 BGI Company Details
        11.14.2 BGI Business Overview
        11.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.14.5 BGI Recent Developments
    11.15 Qiagen
        11.15.1 Qiagen Company Details
        11.15.2 Qiagen Business Overview
        11.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.15.5 Qiagen Recent Developments
    11.16 Perkin Elmer
        11.16.1 Perkin Elmer Company Details
        11.16.2 Perkin Elmer Business Overview
        11.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.16.5 Perkin Elmer Recent Developments
    11.17 Pacific Bioscience
        11.17.1 Pacific Bioscience Company Details
        11.17.2 Pacific Bioscience Business Overview
        11.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.17.5 Pacific Bioscience Recent Developments
    11.18 Partek
        11.18.1 Partek Company Details
        11.18.2 Partek Business Overview
        11.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.18.5 Partek Recent Developments
    11.19 GnuBIO
        11.19.1 GnuBIO Company Details
        11.19.2 GnuBIO Business Overview
        11.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.19.5 GnuBIO Recent Developments
    11.20 Foundation Medicine
        11.20.1 Foundation Medicine Company Details
        11.20.2 Foundation Medicine Business Overview
        11.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.20.5 Foundation Medicine Recent Developments
    11.21 Paradigm
        11.21.1 Paradigm Company Details
        11.21.2 Paradigm Business Overview
        11.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.21.5 Paradigm Recent Developments
    11.22 Caris Life Sciences
        11.22.1 Caris Life Sciences Company Details
        11.22.2 Caris Life Sciences Business Overview
        11.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.22.5 Caris Life Sciences Recent Developments
    11.23 Myriad Genetics
        11.23.1 Myriad Genetics Company Details
        11.23.2 Myriad Genetics Business Overview
        11.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
        11.23.5 Myriad Genetics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
List of Tables
    Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of NGS Pre-Sequencing
    Table 3. Key Players of Sequencing
    Table 4. Key Players of NGS Data Analysis
    Table 5. Key Players of Primary, Secondary & Tertiary Data Analysis
    Table 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2017-2022)
    Table 10. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2023-2028)
    Table 12. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
    Table 13. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
    Table 14. Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
    Table 15. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
    Table 16. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players (2017-2022)
    Table 18. Global Top Clinical Oncology Next Generation Sequencing (NGS) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2021)
    Table 19. Ranking of Global Top Clinical Oncology Next Generation Sequencing (NGS) Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
    Table 23. Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2017-2022)
    Table 27. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2023-2028)
    Table 29. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Application (2017-2022)
    Table 31. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Application (2023-2028)
    Table 33. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022) & (US$ Million)
    Table 34. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028) & (US$ Million)
    Table 35. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022) & (US$ Million)
    Table 36. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028) & (US$ Million)
    Table 37. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022) & (US$ Million)
    Table 38. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022) & (US$ Million)
    Table 40. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028) & (US$ Million)
    Table 41. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022) & (US$ Million)
    Table 42. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028) & (US$ Million)
    Table 43. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028) & (US$ Million)
    Table 49. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2017-2022) & (US$ Million)
    Table 50. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2023-2028) & (US$ Million)
    Table 51. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022) & (US$ Million)
    Table 52. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028) & (US$ Million)
    Table 53. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022) & (US$ Million)
    Table 54. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028) & (US$ Million)
    Table 55. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022) & (US$ Million)
    Table 56. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2023-2028) & (US$ Million)
    Table 63. Illumina Company Details
    Table 64. Illumina Business Overview
    Table 65. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 66. Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 67. Illumina Recent Developments
    Table 68. Roche Company Details
    Table 69. Roche Business Overview
    Table 70. Roche Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 71. Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 72. Roche Recent Developments
    Table 73. Agilent Technologies Company Details
    Table 74. Agilent Technologies Business Overview
    Table 75. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 76. Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 77. Agilent Technologies Recent Developments
    Table 78. Knome Company Details
    Table 79. Knome Business Overview
    Table 80. Knome Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 81. Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 82. Knome Recent Developments
    Table 83. Genomatix Software Company Details
    Table 84. Genomatix Software Business Overview
    Table 85. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 86. Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 87. Genomatix Software Recent Developments
    Table 88. GATC Biotech Company Details
    Table 89. GATC Biotech Business Overview
    Table 90. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 91. GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 92. GATC Biotech Recent Developments
    Table 93. Oxford Nanopore Technologies Company Details
    Table 94. Oxford Nanopore Technologies Business Overview
    Table 95. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 96. Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 97. Oxford Nanopore Technologies Recent Developments
    Table 98. Macrogen Company Details
    Table 99. Macrogen Business Overview
    Table 100. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 101. Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 102. Macrogen Recent Developments
    Table 103. Life Technologies Company Details
    Table 104. Life Technologies Business Overview
    Table 105. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 106. Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 107. Life Technologies Recent Developments
    Table 108. DNASTAR Company Details
    Table 109. DNASTAR Business Overview
    Table 110. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 111. DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 112. DNASTAR Recent Developments
    Table 113. Exosome Diagnostics Company Details
    Table 114. Exosome Diagnostics Business Overview
    Table 115. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 116. Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 117. Exosome Diagnostics Recent Developments
    Table 118. Biomatters Company Details
    Table 119. Biomatters Business Overview
    Table 120. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 121. Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 122. Biomatters Recent Developments
    Table 123. CLC Bio Company Details
    Table 124. CLC Bio Business Overview
    Table 125. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 126. CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 127. CLC Bio Recent Developments
    Table 128. BGI Company Details
    Table 129. BGI Business Overview
    Table 130. BGI Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 131. BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 132. BGI Recent Developments
    Table 133. Qiagen Company Details
    Table 134. Qiagen Business Overview
    Table 135. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 136. Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 137. Qiagen Recent Developments
    Table 138. Perkin Elmer Company Details
    Table 139. Perkin Elmer Business Overview
    Table 140. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 141. Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 142. Perkin Elmer Recent Developments
    Table 143. Pacific Bioscience Company Details
    Table 144. Pacific Bioscience Business Overview
    Table 145. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 146. Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 147. Pacific Bioscience Recent Developments
    Table 148. Partek Company Details
    Table 149. Partek Business Overview
    Table 150. Partek Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 151. Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 152. Partek Recent Developments
    Table 153. GnuBIO Company Details
    Table 154. GnuBIO Business Overview
    Table 155. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 156. GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 157. GnuBIO Recent Developments
    Table 158. Foundation Medicine Company Details
    Table 159. Foundation Medicine Business Overview
    Table 160. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 161. Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 162. Foundation Medicine Recent Developments
    Table 163. Paradigm Company Details
    Table 164. Paradigm Business Overview
    Table 165. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 166. Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 167. Paradigm Recent Developments
    Table 168. Caris Life Sciences Company Details
    Table 169. Caris Life Sciences Business Overview
    Table 170. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 171. Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 172. Caris Life Sciences Recent Developments
    Table 173. Myriad Genetics Company Details
    Table 174. Myriad Genetics Business Overview
    Table 175. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 176. Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022) & (US$ Million)
    Table 177. Myriad Genetics Recent Developments
    Table 178. Research Programs/Design for This Report
    Table 179. Key Data Information from Secondary Sources
    Table 180. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type: 2021 VS 2028
    Figure 2. NGS Pre-Sequencing Features
    Figure 3. Sequencing Features
    Figure 4. NGS Data Analysis Features
    Figure 5. Primary, Secondary & Tertiary Data Analysis Features
    Figure 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2021 VS 2028
    Figure 7. Academic & Clinical Research Case Studies
    Figure 8. Hospitals & Clinics Case Studies
    Figure 9. Pharma & Biotech Entities Case Studies
    Figure 10. Clinical Oncology Next Generation Sequencing (NGS) Report Years Considered
    Figure 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region: 2021 VS 2028
    Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players in 2021
    Figure 15. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2021
    Figure 17. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY (2017-2028) & (US$ Million)
    Figure 18. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2017-2028)
    Figure 19. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Application (2017-2028)
    Figure 20. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Country (2017-2028)
    Figure 21. United States Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2017-2028)
    Figure 25. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Application (2017-2028)
    Figure 26. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Country (2017-2028)
    Figure 27. Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. France Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. U.K. Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Nordic Countries Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY (2017-2028) & (US$ Million)
    Figure 34. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2017-2028)
    Figure 35. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Application (2017-2028)
    Figure 36. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Region (2017-2028)
    Figure 37. China Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. India Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 43. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY (2017-2028) & (US$ Million)
    Figure 44. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2017-2028)
    Figure 45. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Application (2017-2028)
    Figure 46. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Country (2017-2028)
    Figure 47. Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY (2017-2028) & (US$ Million)
    Figure 50. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2017-2028)
    Figure 51. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Application (2017-2028)
    Figure 52. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Country (2017-2028)
    Figure 53. Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. UAE Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Illumina Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 57. Roche Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 58. Agilent Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 59. Knome Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 60. Genomatix Software Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 61. GATC Biotech Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 62. Oxford Nanopore Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 63. Macrogen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 64. Life Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 65. DNASTAR Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 66. Exosome Diagnostics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 67. Biomatters Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 68. CLC Bio Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 69. BGI Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 70. Qiagen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 71. Perkin Elmer Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 72. Pacific Bioscience Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 73. Partek Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 74. GnuBIO Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 75. Foundation Medicine Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 76. Paradigm Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 77. Caris Life Sciences Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 78. Myriad Genetics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2017-2022)
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Frequently Asked Questions
Clinical Oncology Next Generation Sequencing (NGS) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Clinical Oncology Next Generation Sequencing (NGS) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Clinical Oncology Next Generation Sequencing (NGS) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cloud Based Storage

Cloud Based Storage market is segmented by players, region (country), by Type and by Application. ... Read More